Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17192336 | 1.00 | CHRNA7 (0.31) | CHRNA7ESR2 | |
| SCHEMBL20412671 | 0.88 | FEN1 (0.33) | CHRNA7 | |
| SCHEMBL20614189 | 0.87 | CHRNA7 (0.32) | CHRNA7ESR2 | |
| SCHEMBL20842565 | 0.84 | SLC6A4 (0.33) | CHRNA7 | |
| SCHEMBL17189700 | 0.82 | — | — | |
| SCHEMBL20614161 | 0.82 | NOTUM (0.32) | CHRNA7 | |
| SCHEMBL802760 | 0.81 | ESR2 (0.37) | ESR2 | |
| SCHEMBL31026 | 0.81 | ESR2 (0.37) | ESR2 | |
| SCHEMBL17189698 | 0.80 | — | — | |
| SCHEMBL20614170 | 0.79 | HCRTR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628721-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-03-01 | — | — | EP | disclosed |
| US-11370969-B2 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2022-06-28 | — | — | US | disclosed |
| EP-3628721-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2020-04-01 | — | — | EP | disclosed |
| WO-2019115485-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019110636-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-06-13 | — | — | WO | disclosed |
| EP-3284803-B1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2019-01-23 | — | — | EP | disclosed |
| US-20180171231-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| EP-3284803-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-20180044591-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180002604-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-01-04 | — | — | US | disclosed |
| US-20170362506-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-12-21 | — | — | US | disclosed |
| US-20170306232-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| EP-3235894-A2 | LIQUID CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-9512102-B2 | 4,6-difluorodibenzothiophene derivatives | MERCK PATENT GMBH (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20160208170-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20150299161-A1 | 4,6-DIFLUORODIBENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299161-A1 | 4,6-DIFLUORODIBENZOTHIOPHENE DERIVATIVES | DDT, CD2, CYP4F2 | CHRNA7 4010/4885ESR2 888/4885 |
| US-20160208170-A1 | LIQUID-CRYSTALLINE MEDIUM | NEFM, VIM, PLG | CHRNA7 3935/4885ESR2 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.